Aster DM Healthcare Announces Q4FY26 Investor Presentation with Strong Performance
Aster DM Healthcare announced its Q4FY26 investor presentation scheduled for May 1, 2026, showcasing robust combined entity performance with ₹2,361 crores revenue (18% growth) and ₹517 crores operating EBITDA (25% growth). The QCIL merger received overwhelming 96.68% shareholder approval and is expected to complete in Q1 FY27, creating a combined network of 10,623 beds with 4,445 additional beds planned for expansion.
*this image is generated using AI for illustrative purposes only.
Aster DM Healthcare has announced its investor presentation for the earnings conference call scheduled for May 1, 2026, following the release of audited financial results for the quarter and year ended March 31, 2026. The healthcare services provider continues to demonstrate strong operational performance while advancing its strategic merger with QCIL.
Combined Entity Performance Highlights
The combined proforma entity (Aster + QCIL) delivered robust financial performance for Q4FY26, showcasing significant growth across key operational metrics.
| Performance Metric: | Q4FY26 | Q4FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations: | ₹2,361 crores | ₹2,002 crores | +18% |
| Operating EBITDA: | ₹517 crores | ₹414 crores | +25% |
| Operating EBITDA Margin: | 21.90% | 20.70% | +120 bps |
| Total Patient Volumes: | 1.93 million | - | +12% YoY |
| Occupancy Rate: | 61% | - | +210 bps |
Aster Standalone Financial Performance
Aster's standalone operations demonstrated strong momentum with significant improvements in profitability and operational efficiency during Q4FY26.
| Financial Metric: | Q4FY26 | Q4FY25 | Growth (%) |
|---|---|---|---|
| Revenue from Operations: | ₹1,182 crores | ₹1,000 crores | +18% |
| Operating EBITDA: | ₹244 crores | ₹193 crores | +26% |
| Operating EBITDA Margin: | 20.70% | 19.30% | +140 bps |
| Normalised PAT: | ₹140 crores | ₹106 crores | +32% |
| Capacity Beds: | 5,449 | 5,000 | +9% |
Merger Implementation Progress
The proposed merger between Aster DM Healthcare and QCIL has received overwhelming shareholder approval, with 96.68% of total votes cast in favor of the transaction. The merger is expected to be completed in Q1 FY27, creating one of India's largest hospital networks.
| Merger Details: | Status |
|---|---|
| Shareholder Approval: | 96.68% votes in favor |
| Expected Completion: | Q1 FY27 |
| Combined Bed Capacity: | 10,623 beds |
| Pipeline Expansion: | 4,445 additional beds planned |
Operational Excellence and Expansion
The company added 373 beds during the year, bringing total bed capacity to 10,623 beds as of March 31, 2026. The expansion strategy focuses on both brownfield and greenfield projects, with 56% of beds planned in existing facilities and 44% in new facilities.
Aster's mature hospitals (over 7 years) continue to demonstrate strong performance with 26.20% operating EBITDA margins and 36.50% return on capital employed. The company's focus on niche specialties and high-end procedures has resulted in improved average revenue per patient and better case mix across its network.
The combined entity's strong financial performance and successful merger progress position it well for continued growth in India's expanding healthcare market, with significant synergies expected post-merger completion.
Historical Stock Returns for Aster DM Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.22% | +2.45% | +4.95% | +0.17% | +36.95% | +382.15% |
What specific synergies does Aster expect to realize post-merger completion in Q1 FY27, and how might these impact the combined entity's EBITDA margins?
How will the addition of 4,445 planned beds affect Aster's market positioning against competitors like Apollo Hospitals and Fortis Healthcare?
What regulatory approvals remain pending for the Aster-QCIL merger, and could any delays impact the Q1 FY27 completion timeline?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
